An HSV-1 gD mutant virus as an entry-impaired live virus vaccine.
HSV-1 glycoprotein D (gD) interacts with HVEM and nectin-1 cell receptors to initiate virus entry. We prepared an HSV-1 strain with mutations in the gD gene at amino acid residues 3 and 38 by changing alanine to cysteine and tyrosine to cysteine, respectively (A3C/Y38C). These mutations were constructed with the intent of evaluating infection in vivo when virus enters by HVEM but not nectin-1 receptors and were based on prior reports demonstrating that purified gDA3C/Y38C protein binds to HVEM but not to nectin-1. While preparing a high-titered purified virus pool, the cysteine mutation at position 38 reverted to tyrosine, which occurred on two separate occasions. The resultant HSV-1 strain, KOS-gDA3C, had a single amino acid mutation at residue 3 and exhibited reduced entry into both HVEM and nectin-1 expressing cells. When tested in the murine flank model, the mutant virus was markedly attenuated for virulence and caused only mild disease, while the parental and rescued viruses produced much more severe disease. Thirty days after KOS-gDA3C infection, mice were challenged with a lethal dose of HSV-1 and were highly resistant to disease. The KOS-gDA3C mutation was stable during 30 passages in vitro and was present in each of 3 isolates obtained from infected mice. Therefore, this gD mutant virus impaired in entry may represent a novel candidate for an attenuated live HSV-1 vaccine.
Awasthi
Sita
S
Infectious Disease Division, Department of Medicine, School of Medicine, Philadelphia, PA 19104-6073, USA. sawasthi@mail.med.upenn.edu
Lubinski
John M
JM
Eisenberg
Roselyn J
RJ
Cohen
Gary H
GH
Friedman
Harvey M
HM
D000818:Animals; D015815:Cell Adhesion Molecules / Q000378:metabolism; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D005260:Female; D006561:Herpes Simplex / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000472:pathogenicity*; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D000075983:Nectins; D053240:Receptors, Tumor Necrosis Factor, Member 14 / Q000378:metabolism; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology
D015815:Cell Adhesion Molecules; D022301:Herpes Simplex Virus Vaccines; C000619010:NECTIN1 protein, human; C000619015:Nectin1 protein, mouse; D000075983:Nectins; D053240:Receptors, Tumor Necrosis Factor, Member 14; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; C039447:glycoprotein D, Human herpesvirus 1